Polydatin ameliorates DSS-induced colitis in mice through inhibition of nuclear factor-kappaB activation.

Jun Yao,Jian-Yao Wang,Lei Liu,Wei-Sen Zeng,Ying-Xue Li,An-Ying Xun,Li Zhao,Chun-Hong Jia,Ju-Ling Feng,Xiao-Xia Wei,Li-Sheng Wang
DOI: https://doi.org/10.1055/s-0030-1250462
IF: 3.007
2011-01-01
Planta Medica
Abstract:Nuclear factor-kappa B (NF-kappa B) plays a pivotal role in the regulation of immune and inflammatory responses. The real-time expression level of NF-kappa B reflects the development of ulcerative colitis (UC). Polydatin has vast pharmacological activities, including inhibiting the production of inflammatory mediators, inducing the production of antioxidants, regulating immune function, etc. The purpose of this study was to investigate the potential inhibitory effects of polydatin on NF-kappa B pathway activation in a mouse UC model. The results showed that polydatin treatment downregulated NF-kappa B p65 activity and expression, blocked the expression of TNF-alpha, IL-6 and IL-1 beta at both mRNA and protein levels, decreased myeloperoxidase (MPO) activity, and alleviated inflammatory damage of colitis in mice with UC (p < 0.05), suggesting that the anti-inflammation effects of polydatin can be attributed, at least partially, to the blocking of the NF-kappa B pathway.
What problem does this paper attempt to address?